Shares of Urogen Pharma (URGN) have gained 5.4% over the past four weeks to close the last trading session at 15.82,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof42.88 indicates a potential upside of 171.1%. The average comprises four short-term price targets ranging from a low of 18toahighof60, with a standard deviation of $18.56. While the lowest estimate indicates ...